Q-omics provides the consensus-scored RPL29P24 profile across patient tissues and cancer cell-line models. RPL29P24 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RPL29P24 is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, RPL29P24 RNA expression shows 17,776 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, COAD, and UVM as cancer lineages where RPL29P24 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL29P24 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL29P24 survival associations across molecular data types. RPL29P24 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL29P24 RNA expression–survival associations across cancer types. High RPL29P24 expression shows unfavorable associations in KIRC and STAD, but favorable associations in HNSC, UCS, COAD and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify KIRC as the clearest survival context for RPL29P24 RNA expression.
This table summarizes RPL29P24 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RPL29P24. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL29P24 shows lower tumor expression in ESCA and higher tumor expression in COAD, LUSC, LIHC, KIRC and LUAD. The COAD box plot shows higher RPL29P24 RNA expression in tumor versus normal tissue (log2 FC = +0.405, t-test p < 0.001).
This table shows molecular features associated with RPL29P24 in patient tissues and cancer cell lines. In patient samples, RPL29P24 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
